CG MED EQUIP.
838810
BEOKA
870199
Shenzhen Bromake New Material
301387
4
Zhejiang Hongchang Electrical Technology
301008
5
Wuhan Lincontrol Automotive Electronics Co., Ltd.
688667
CN Stock MarketDetailed Quotes
688488 Jiangsu Aidea Pharmaceutical
- 12.08
- +0.72+6.34%
Market Closed Apr 30 15:00 CST
5.08BMarket Cap-45.41P/E (TTM)
12.17High11.30Low219.84KlotVolume11.48Open11.36Pre Close258.90MTurnover5.23%Turnover RatioLossP/E (Static)420.78MShares17.1752wk High5.10P/B5.08BFloat Cap6.5852wk Low13.63Limit Up420.78MShs Float45.21Historical High9.09Limit Down7.66%Amplitude6.58Historical Low--Dividend TTM11.78Avg Price80.68KlotAsk--Div YieldTTM100Lot Size130.47KlotBid
Jiangsu Aidea Pharmaceutical News
Eddy Pharmaceuticals: Notice of Eddy Pharmaceuticals to convene the 2024 Annual Shareholders\' Meeting
Eddy Pharmaceutical: Eddy Pharmaceutical 2024 Independent Director Debriefing Report (Qi Xiaoyan)
Eddy Pharmaceuticals: Eddy Pharmaceuticals 2024 Independent Director Debriefing Report (Wang Guangji)
Eddy Pharmaceuticals: Eddy Pharmaceuticals 2024 Independent Director Debriefing Report (Guo Zijian)
Eddy Pharmaceuticals 2024 Accounting Firm Performance Assessment Report
Eddy Pharmaceuticals 2024 Internal Control Evaluation Report
Notice of Eddy Pharmaceuticals to convene the 2024 Annual Shareholders\' Meeting
Special Report by the Board of Directors of Eddy Pharmaceuticals on the 2024 Independent Directors\' Independence Self-Audit
Eddy Pharmaceutical 2024 Board Audit Committee Performance Report
Eddy Pharmaceuticals Announcement on 2024 Asset Impairment Preparation
Eddy Pharmaceuticals 2024 “Improve Quality, Increase Efficiency, and Focus on Rewards” Action Plan Evaluation Report and 2025 Action Plan
Report of the Audit Committee of the Board of Directors of Eddy Pharmaceuticals on the implementation of supervisory duties by accounting firms in 2024
Eddy Pharmaceutical: Eddy Pharmaceutical\'s Voluntary Disclosure Notice on the Termination of the Project Cooperation and Development Framework Contract with Nanjing Pharmaceutical Stone Technology Co., Ltd.
Eddy Pharmaceutical\'s Voluntary Disclosure Notice on the Termination of the Framework Contract for Project Cooperation and Development with Nanjing Pharmaceutical Stone Technology Co., Ltd.
Eddy Pharmaceutical\'s announcement on the completion of the general election of the company\'s board of directors and board of supervisors and the appointment of senior management and securities affairs representatives
Legal Opinion of Jiangsu Century Tongren Law Firm on the 2025 First Extraordinary General Meeting of Shareholders of Jiangsu Eddy Pharmaceutical Co., Ltd.
Announcement of Resolutions of Eddy Pharmaceutical\'s 2025 First Extraordinary General Meeting of Shareholders
Eddy Pharmaceuticals: Eddy Pharmaceuticals 2025 First Extraordinary Shareholders\' Meeting Meeting Information
Eddy Pharmaceuticals 2025 First Extraordinary Shareholders\' Meeting Meeting Information
Eddy Pharmaceuticals: Eddy Pharmaceuticals Independent Director Nominee Statement and Commitment - Guo Zijian